AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Marker Therapeutics Inc (NASDAQ:MRKR)
1.45 USD
+0.030 2.113%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.42 |
|---|---|
| Change | +0.030 2.113% |
| 52 W H/L (in USD) | 9.680/1.570 |
| EBITDA (in USD) | -11.792M |
| PE Ratio | -- |
| Volume | 23302 |
| Diluted Eps TTM | -1.31 |
| Total Assets (in USD) | 17.127M |
|---|---|
| Total Liabilities (in USD) | 3.075M |
| Revenue TTM (in USD) | 3.321M |
| Cash (in USD) | 15.111M |
| Market Cap (in USD) | 35.052 M |
| Revenue Per Share TTM | 0.375 |
| Gross Profit TTM (in USD) | -17.126M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Employees: 8
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Peter L. Hoang MBA | Pres, CEO & Director | 1972 |
| 2. | Dr. Mythili Koneru M.D., Ph.D. | Chief Medical Officer | 1978 |
| 3. | Dr. Juan F. Vera M.D. | Co-Founder, COO, Chief Scientific Officer & Director | 1980 |
| 4. | Mr. Michael J. Loiacono | Chief Accounting Officer, Treasurer & Sec. | 1966 |
| 5. | Ms. Elizabeth Donnelly | Director of Admin. | NA |
| 6. | Mr. Edmund Cheung | VP of HR | NA |
| 7. | Dr. Nadia Agopyan Ph.D. | Sr. VP of Regulatory Affairs | NA |
| 8. | Dr. Robert Z. Florkiewicz Sr. | Sr. Director of Molecular Biology & Virology | NA |
| 9. | Dr. Juan F. Vera M.D. | Co-Founder, CEO, President, Treasurer & Director | 1981 |
| 10. | Ms. Elizabeth Donnelly | Director of Administration | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.380 0.886% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -29.931M | -41.879M | -28.706M | -21.428M | -147.958M |
| Minority Interest | - | - | - | - | - |
| Net Income | -29.916M | -41.873M | -28.526M | -20.327M | -147.958M |
| Selling General Administrative | 12.82M | 12.925M | 10.472M | 9.977M | 24.38M |
| Gross Profit | 9.005M | 1.242M | 0.467M | 0.213M | 0.206M |
| Reconciled Depreciation | 3.68M | 3.163M | 1.076M | 0.287M | - |
| Ebit | -29.946M | -39.478M | -28.886M | -22.529M | -148.345M |
| Ebitda | -26.265M | -36.315M | -27.841M | -22.26M | -148.132M |
| Depreciation And Amortization | 3.68M | 3.163M | 1.045M | 0.269M | 0.214M |
| Operating Income | -29.946M | -39.478M | -28.886M | -22.529M | -148.172M |
| Other Operating Expenses | 38.959M | 40.72M | 29.353M | 22.742M | 148.378M |
| Interest Expense | -0.015M | 0.006M | 0.149M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 0.248M | 0.006M | 0.149M | 1.083M | 0.254M |
| Net Interest Income | 0.248M | 0.006M | 0.149M | 1.083M | 0.254M |
| Income Tax Expense | -0.015M | -0.006M | -0.18M | -1.101M | -0.214M |
| Total Revenue | 9.005M | 1.242M | 0.467M | 0.213M | 0.206M |
| Total Operating Expenses | 38.959M | 40.72M | 29.353M | 22.742M | 148.378M |
| Cost Of Revenue | - | - | - | 12.765M | 123.998M |
| Total Other Income Expense Net | 0.015M | -2.401M | 0.18M | 1.101M | -0.04M |
| Net Income From Continuing Ops | -29.931M | -41.879M | -28.706M | -21.428M | -147.958M |
| Net Income Applicable To Common Shares | - | -41.879M | -28.706M | -21.428M | -147.958M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 17.127M | 34.422M | 68.135M | 45.615M | 46.359M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 0.988M | 2.435M | 3.631M | 3.058M | 1.526M |
| Total Liab | 3.075M | 14.821M | 24.15M | 18.27M | 2.273M |
| Total Stockholder Equity | 14.053M | 19.601M | 43.986M | 27.345M | 44.086M |
| Other Current Liab | 2.114M | 3.093M | 5.991M | 0M | 0.031M |
| Common Stock | 0.009M | 0.008M | 0.083M | 0.051M | 0.046M |
| Capital Stock | 0.009M | 0.008M | 0.083M | 0.051M | 0.046M |
| Retained Earnings | -436.286M | -428.049M | -398.118M | -356.239M | -327.533M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | -0M | -0M | -0M |
| Cash | 15.111M | 11.782M | 42.351M | 21.352M | 43.904M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 3.075M | 7.782M | 12.902M | 6.402M | 1.993M |
| Current Deferred Revenue | - | 2.5M | 1.146M | 3.078M | 0.765M |
| Net Debt | -15.111M | -4.166M | -30.483M | -9.095M | -43.42M |
| Short Term Debt | - | 0.577M | 0.62M | 0.389M | 0.204M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | - | 7.617M | 11.868M | 12.257M | 0.484M |
| Other Stockholder Equity | 450.33M | 447.642M | 442.021M | 383.533M | 371.574M |
| Property Plant Equipment | - | - | 22.153M | 6.789M | 0.873M |
| Total Current Assets | 17.127M | 16.619M | 45.982M | 24.411M | 45.487M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 1.028M | 2.402M | 0M | 1.001M | 0.056M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 0M | - | - | -1M | - |
| Accounts Payable | 0.961M | 1.612M | 5.144M | 2.935M | 0.993M |
| Accumulated Other Comprehensive Income | - | - | - | - | -0.105M |
| Non Currrent Assets Other | - | - | 2.226M | -0M | -0M |
| Non Current Assets Total | 0M | 17.803M | 22.153M | 21.204M | 0.873M |
| Capital Lease Obligations | - | 7.617M | 11.868M | 12.257M | 0.484M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -4.945M | -3.131M | -10.428M | -0.375M | -0.148M |
| Total Cashflows From Investing Activities | - | -3.131M | -10.428M | -0.375M | -0.148M |
| Total Cash From Financing Activities | 0.202M | 52.556M | 6.736M | 0.816M | 71.245M |
| Net Income | -29.931M | -41.879M | -28.706M | -21.428M | -147.958M |
| Change In Cash | -31.715M | 22.145M | -22.552M | -17.843M | 56.617M |
| Begin Period Cash Flow | 43.497M | 21.352M | 43.904M | 61.747M | 5.129M |
| End Period Cash Flow | 11.782M | 43.497M | 21.352M | 43.904M | 61.747M |
| Total Cash From Operating Activities | -26.972M | -27.28M | -18.86M | -18.284M | -14.48M |
| Depreciation | 3.68M | 3.163M | 1.076M | 0.287M | 0.287M |
| Other Cashflows From Investing Activities | - | - | -3.639M | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | 6.736M | 0.816M | -0.072M |
| Other Cashflows From Financing Activities | -4.945M | 0.003M | 0.55M | 0.816M | 4.372M |
| Capital Expenditures | 4.945M | 3.131M | 10.428M | 0.375M | 0.148M |
| Change In Working Capital | -5.813M | 5.472M | 3.573M | -2.482M | 1.043M |
| Other Non Cash Items | -0.253M | 0M | -0.031M | -0.018M | 116.085M |
| Free Cash Flow | -31.917M | -30.411M | -29.288M | -18.659M | -14.628M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 143582 |
| 2. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 87137 |
| 3. | Fidelity Extended Market Index | 2 years ago | 37931 |
| 4. | WEALTHGATE Biotech Aggressive Fund I | 2 years ago | 25442 |
| 5. | DFA US Small Cap I | 2 years ago | 15900 |
| 6. | WEALTHGATE Biotech Fund Inst | 2 years ago | 9508 |
| 7. | Fidelity Series Total Market Index | 2 years ago | 9019 |
| 8. | Fidelity Total Market Index | 2 years ago | 8951 |
| 9. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 5797 |
| 10. | Vifag 2002 SICAV | 2 years ago | 5552 |
| 11. | Fidelity Nasdaq Composite Index | 2 years ago | 5272 |
| 12. | Northern Trust Extended Eq Market Idx | 2 years ago | 4752 |
| 13. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 4752 |
| 14. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 4656 |
| 15. | Dimensional US Small Cap ETF | 2 years ago | 4378 |
| 16. | Spartan Total Market Index Pool E | 2 years ago | 3793 |
| 17. | Vanguard U.S. Eq Idx £ Acc | 2 years ago | 2512 |
| 18. | Spartan Extended Market Index Pool E | 2 years ago | 2039 |
| 19. | SSgA U.S. Extended Market Index Class I | 2 years ago | 2030 |
| 20. | State St US Extended Mkt Indx NL Cl C | 2 years ago | 2030 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Northern Trust Corp | 2 years ago | 38711 |
| 2. | NEA Management Company, LLC | 2 years ago | 1071428 |
| 3. | Aisling Capital Management LP | 2 years ago | 314286 |
| 4. | Vanguard Group Inc | 2 years ago | 233231 |
| 5. | Wedbush Morgan Securities Inc | 2 years ago | 69500 |
| 6. | Geode Capital Management, LLC | 2 years ago | 60047 |
| 7. | Renaissance Technologies Corp | 2 years ago | 37550 |
| 8. | Dimensional Fund Advisors, Inc. | 2 years ago | 20278 |
| 9. | State Street Corporation | 2 years ago | 19748 |
| 10. | Creative Planning Inc | 2 years ago | 17312 |
| 11. | Matrix Asset Advisors Inc | 2 years ago | 15000 |
| 12. | Advisor Group Holdings, Inc. | 2 years ago | 6385 |
| 13. | Morgan Stanley - Brokerage Accounts | 2 years ago | 3598 |
| 14. | Bank of America Corp | 2 years ago | 2334 |
| 15. | Riggs Asset Management Co Inc | 2 years ago | 1400 |
| 16. | BlackRock Inc | 2 years ago | 1364 |
| 17. | Tower Research Capital LLC | 2 years ago | 1312 |
| 18. | U.S. Bancorp | 2 years ago | 839 |
| 19. | Wells Fargo & Co | 2 years ago | 283 |
| 20. | Group One Trading, LP | 2 years ago | 178 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...